Last reviewed 2026-04-20 · How we verify

ZAVEGEPANT

Zavegepant blocks CGRP receptors to prevent migraine.

At a glance

Mechanism of action

Zavegepant works by blocking the calcitonin gene-related peptide (CGRP) receptors, which are involved in the transmission of pain signals during migraines. By inhibiting these receptors, Zavegepant helps reduce the symptoms of migraines.

Approved indications

No approved indications tracked.

Common side effects

• Taste Disorders
• Nausea
• Nasal Discomfort
• Vomiting

Serious adverse events

• Hypersensitivity (including anaphylaxis, facial swelling, urticaria)
• Hypertension
• Raynaud's Phenomenon

Key clinical trials

• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine (PHASE1)
• A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling (PHASE1)
• A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants (PHASE3)
• Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications (PHASE4)
• A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults (PHASE3)
• Acute Migraine Treatment in the ED With Gepants (PHASE4)
• A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (PHASE2, PHASE3)
• A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ZAVEGEPANT CI brief — competitive landscape report
• ZAVEGEPANT updates RSS · CI watch RSS